Sheridan D P, Card R T, Pinilla J C, Harding S M, Thomson D J, Gauthier L, Drotar D
Department of Medicine, University of Saskatchewan, Saskatoon.
Can J Surg. 1994 Feb;37(1):33-6.
To determine whether desmopressin acetate (DDAVP) has the ability to reduce blood loss in patients with a known bleeding tendency.
A randomized, double-blind, placebo controlled study.
A university teaching hospital.
Men under the age of 70 years who had taken acetylsalicylic acid within 7 days of scheduled coronary artery bypass surgery. Patients with an abnormal hematologic profile or a history of bleeding or who were receiving heparin or undergoing repeat coronary bypass surgery were excluded. Forty-four patients were randomized with restriction in blocks of 10; 20 received DDAVP and 24 received a placebo.
Blood loss and blood transfusion requirements.
Patients treated with DDAVP lost significantly (p < 0.01) less blood than those receiving a placebo (1543 mL versus 2376 mL respectively). Nineteen patients had a blood loss of more than 2000 mL; 15 of these were in the placebo group. Significantly (p < 0.02) fewer patients receiving DDAVP required blood transfusion (9 versus 18).
DDAVP reduces blood loss during cardiac bypass surgery in patients who have taken acetylsalicylic acid within 7 days before operation.
确定醋酸去氨加压素（DDAVP）是否有能力减少已知有出血倾向患者的失血量。
一项随机、双盲、安慰剂对照研究。
一所大学教学医院。
计划进行冠状动脉搭桥手术前7天内服用过乙酰水杨酸的70岁以下男性。排除血液学检查异常或有出血史、正在接受肝素治疗或正在进行再次冠状动脉搭桥手术的患者。44例患者按10例一组进行限制性随机分组；20例接受DDAVP治疗，24例接受安慰剂治疗。
失血量和输血需求。
接受DDAVP治疗的患者失血量明显（p<0.01）少于接受安慰剂的患者（分别为1543毫升和2376毫升）。19例患者失血量超过2000毫升；其中15例在安慰剂组。接受DDAVP治疗的患者需要输血的人数明显（p<0.02）较少（9例对18例）。
DDAVP可减少术前7天内服用过乙酰水杨酸的患者在心脏搭桥手术期间的失血量。
